Our results showed only discreet effects during the cardiotoxic ISO action on the endogenous cardiac NADH dehydrogenase activity, since only after 2 and 4 days of treatment (in the post-infarction stage), was observed an enhancement and a tendency to increase the maximal NADH oxidation (Figure 4). The gene discussed is ENSG00000251605; the disease is infarction.